Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 11, 2016, Pages 2220-2228

  Puri, Rishi ^a,b   Nissen, Steven E ^a   Shao, Mingyuan ^a   Elshazly, Mohamed B ^a   Kataoka, Yu ^c   Kapadia, Samir R ^a   Tuzcu, E Murat ^a   Nicholls, Stephen J ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

atherosclerosis; low density lipoprotein; non HDL; residual risk; triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL ESTER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCENT ATHEROMA VOLUME; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; AGED; BLOOD; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DRUG EFFECTS; INTERVENTIONAL ULTRASONOGRAPHY; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84981742303     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307601     Document Type: Article

References (34)

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
2. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005; 46: 1225-1228. doi: 10.1016/j. jacc.2005.07.006.
3. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Nonhigh- density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005; 112: 3375-3383. doi: 10.1161/CIRCULATIONAHA.104.532499.
4. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294: 326-333. doi: 10.1001/jama.294.3.326.
5. Arsenault BJ, Rana JS, Stroes ES, Després JP, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009; 55: 35-41. doi: 10.1016/j. jacc.2009.07.057.
6. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307: 1302-1309. doi: 10.1001/jama.2012.366.
7. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 pt B): 2889-2934. doi: 10.1016/j.jacc.2013.11.002.
8. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.
9. Grundy SM; Expert Dyslipidemia Panel. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013; 7: 561-565. doi: 10.1016/j. jacl.2013.10.001.
10. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015; 9: 129-169. doi: 10.1016/j.jacl.2015.02.003.
11. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet. 2010; 375: 1634-1639. doi: 10.1016/S0140-6736(10)60545-4.
12. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45: 1345-1352. doi: 10.1038/ng.2795.
13. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61: 427-436. doi: 10.1016/j. jacc.2012.08.1026.
14. Zilversmit DB. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res. 1973; 33: 633-638.
15. Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging. 2011; 4: 319-333. doi: 10.1161/CIRCIMAGING.110.962001.
16. Puri R, Tuzcu EM, Nissen SE, Nicholls SJ. Exploring coronary atherosclerosis with intravascular imaging. Int J Cardiol. 2013; 168: 670-679. doi: 10.1016/j.ijcard.2013.03.024.
17. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010; 55: 2399-2407. doi: 10.1016/j.jacc.2010.02.026.
18. Puri R, Wolski K, Uno K, Kataoka Y, King KL, Crowe TD, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ. Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. JACC Cardiovasc Interv. 2013; 6: 29-35. doi: 10.1016/j.jcin.2012.09.006.
19. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013; 226: 178-185. doi: 10.1016/j. atherosclerosis.2012.10.065.
20. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365: 2078-2087. doi: 10.1056/NEJMoa1110874.
21. Fruchart JC, Davignon J, Hermans MP, et al; Residual Risk Reduction Initiative (R3i). Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014; 13: 26. doi: 10.1186/1475-2840-13-26.
22. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000. doi: 10.1001/jama.2009.1619.
23. Varbo A, Nordestgaard BG. Remnant cholesterol and ischemic heart disease. Curr Opin Lipidol. 2014; 25: 266-273. doi: 10.1097/ MOL.0000000000000093.
24. Chapman MJ, Ginsberg HN, Amarenco P, et al; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32: 1345-1361. doi: 10.1093/eurheartj/ehr112.
25. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384: 626-635. doi: 10.1016/S0140-6736(14)61177-6.
26. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574.
27. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367: 309-318. doi: 10.1056/NEJMoa1203859.
28. Zambon A, Puato M, Faggin E, Grego F, Rattazzi M, Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. Atherosclerosis. 2013; 230: 106-109. doi: 10.1016/j.atherosclerosis.2013.06.024.
29. Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al-Hijji MA, Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). J Am Coll Cardiol. 2013; 62: 1960-1965. doi: 10.1016/j.jacc.2013.07.045.
30. Kilgore M, Muntner P, Woolley JM, Sharma P, Bittner V, Rosenson RS. Discordance between high non-HDL cholesterol and high LDLcholesterol among US adults. J Clin Lipidol. 2014; 8: 86-93. doi: 10.1016/j. jacl.2013.11.001.
31. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation. 2002; 106: 3143-3421.
32. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337-345. doi: 10.1161/CIRCOUTCOMES.110.959247.
33. Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. 2013; 111: 506-509. doi: 10.1016/j. amjcard.2012.10.037.
34. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119: 931-939. doi: 10.1161/ CIRCULATIONAHA.108.816181.